SCHEMBL13935565

SCHEMBL13935565

O=C(OCC1CCC2OC2C1)c1cc(C(=O)OCC2CCC3OC3C2)cc(C(=O)OCC2CCC3OC3C2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HTT P42858 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
JMJD6 Q6NYC1 2/20 0.40
LMNA P02545 1/20 0.37
FPR1 P21462 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CARM1 Q86X55 1/20 0.36
PRMT6 Q96LA8 1/20 0.36
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
PPM1B O75688 2/20 0.35
HTR4 Q13639 3/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNA5 P30532 1/20 0.34
CHRNA7 P36544 1/20 0.34
CHRNA4 P43681 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL259056 0.91 DRD2 (0.44) JMJD6CARM1PRMT6DRD2DRD4
SCHEMBL14163687 0.89 JMJD6 (0.38) KDM4EALDH1A1HTTMEN1KMT2A
SCHEMBL28193768 0.85 DRD2 (0.43) CARM1PRMT6DRD2DRD4PPM1B
SCHEMBL28973816 0.85 JMJD6 (0.40) KDM4EALDH1A1L3MBTL1JMJD6LMNA
SCHEMBL11494480 0.82 CHRNB4 (0.43) ALDH1A1L3MBTL1CHRNB2CHRNA4NPC1
SCHEMBL29690854 0.82 CHRNB4 (0.43) ALDH1A1L3MBTL1CHRNB2CHRNA4NPC1
SCHEMBL14154791 0.81 DRD2 (0.38) JMJD6CARM1PRMT6DRD2DRD4
SCHEMBL17012024 0.80 PPM1B (0.35) KDM4ELMNAPPM1B
SCHEMBL21919183 0.80 PPM1B (0.35) KDM4ELMNAPPM1B
SCHEMBL21919411 0.80 PPM1B (0.35) KDM4ELMNAPPM1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090041945-A1 ACTIVE RAY CURABLE COMPOSITION, POLYMERIZATION METHOD, ACTIVE RAY CURABLE INK, IMAGE FORMING METHOD, AND INK-JET RECORDING APPARATUS KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2009-02-12 US disclosed
US-20090041945-A1 ACTIVE RAY CURABLE COMPOSITION, POLYMERIZATION METHOD, ACTIVE RAY CURABLE INK, IMAGE FORMING METHOD, AND INK-JET RECORDING APPARATUS KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2009-02-12 US disclosed
US-7390840-B2 Active ray curable composition, active ray curable ink, image forming method and inkjet recording apparatus utilizing the same KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2008-06-24 US disclosed
EP-1840148-A1 POLYMERIZABLE ACTINIC RADIATION CURABLE COMPOSITION, POLYMERIZATION METHOD, ACTINIC RADIATION CURABLE INK AND IMAGE FORMATION METHOD, AND INK JET RECORDING APPARATUS AND EPOXY COMPOUND Konica Minolta Medical & Graphic, Inc. (JP) 2007-10-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090041945-A1 ACTIVE RAY CURABLE COMPOSITION, POLYMERIZATION METHOD, ACTIVE RAY CURABLE INK, IMAGE FORMING METHOD, AND INK-JET RECORDING APPARATUS RIF1, NAP1L4, NAP1L1 KDM4E 1281/4885ALDH1A1 2785/4885HTT 2232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.